The complexes [(CuL) 2 (XO 4 )]·nH 2 O (HL = pyridine-2-carbaldehyde thiosemicarbazone, X = HP, n = 6; X = Mo, n = 1), [{CuL(ptp)} 2 ]·4H 2 O (Hptp = p-tritylphenol) and [{CuL(tip)} 2 ] (Htip = 2,4,6-triiodophenol) have been prepared from the reaction of aqueous solutions of [{CuL(CH 3 CO 2 )} 2 ] with salts of the appropriate oxygen donor. Also prepared were [{Cu(HL)(H 2 PO 4 )} 2 ][H 2 PO 4 ] 2 ·xH 3 PO 4 ·nH 2 O (x = 0, n = 3; x = 2, n = 2) from the reaction of [{CuL(CH 3 CO 2 )} 2 ] with 2 mol dm -3 H 3 PO 4 and phosphate species (arising from the hydrolysis of 2 mol dm -3 HPF 6 ) respectively. The complexes have been characterized by a range of physicochemical techniques and the crystal and molecular structure of [{Cu(HL)(H 2 PO 4 )} 2 ][H 2 PO 4 ] 2 ·2H 3 PO 4 ·2H 2 O determined by single-crystal X-ray diffraction. The complex cation is a centrosymmetric dimer, the monomeric units having one-atom bridges from two H 2 PO 4 - anions. The copper atom has a distorted square-pyramidal geometry with three donor atoms (NNS) from the neutral, tridentate HL ligand and the fourth in-plane donor (an oxygen) from the bridging anion. The fifth position is occupied by a less strongly bound oxygen from the second bridging anion. An extensive hydrogen-bonding scheme involving the bridging H 2 PO 4 - anions, non-co-ordinated H 2 PO 4 - anions, H 3 PO 4 moieties, water molecules and ligand exists with one very strong contact of 2.436 Å. These complexes may serve as simple models for the interaction of this antitumour system with oxygen donors.
No takes yet. Share an insight, caveat, or question.
Ainscough et al. (1997) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: